MarketPeel
Insider Trading Intelligence
Pricing
…
MH

Michael Thomas Henderson

BBIO
CHIEF BUSINESS OFFICER · BRIDGEBIO PHARMA, INC. · CIK 0001779990
FILING MIX · LIFETIME26%/74%
BUYS
37
SELLS
107
TOTAL VALUE
$47.76M
COMPANIES
3
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
1,089,049
AVG SELL PX
$67.69
TRADE KIND
SHOWING 144 / 144
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
79 backtested trades · 8 horizons · 101 pending
Forward-return performance of every backtestable P/S trade by Michael Thomas Henderson, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d79+35.44%+2.11%+0.58%+1.53%+1.05%1.55
14d79+29.11%+3.39%+1.23%+2.56%+3.89%1.61
30d79+44.30%+3.88%+1.18%+2.70%+0.63%1.57
60d79(4 pending)+46.67%+7.71%+3.02%+4.69%-2.09%1.81
90d79(7 pending)+38.89%+10.60%+3.73%+6.87%+1.70%2.26
180d79(19 pending)+36.67%+28.69%+11.85%+17.25%+9.98%2.96
1y79(27 pending)+21.15%+63.83%+29.73%+34.10%+43.09%4.95
2y79(44 pending)+100.00%-68.04%+37.98%-106.02%-100.71%-34.90
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
BBIO · 4,456 shares · as of Dec 15, 2020
071,053142,106213,158284,211SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 37 buys / 107 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
20,000$100.00$2.00M68,606Jun 22, 2026Jun 23, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
80,000$132.54$10.60M1,015,987Jun 22, 2026Jun 24, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
614$86.89$53.4K1,095,987Jun 10, 2026Jun 12, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,305$86.27$198.9K1,096,601Jun 10, 2026Jun 12, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,654$82.78$633.6K1,101,563Jun 10, 2026Jun 12, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,080$84.18$90.9K1,100,483Jun 10, 2026Jun 12, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,577$85.19$134.3K1,098,906Jun 10, 2026Jun 12, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
6,770$82.21$556.6K1,109,217Jun 10, 2026Jun 12, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
8,026——8,026May 27, 2026May 29, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
18,659$82.05$1.53M1,117,328May 13, 2026May 15, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,341$82.58$110.7K1,115,987May 13, 2026May 15, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
24,814$74.76$1.86M107,875May 8, 2026May 8, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
19,269$75.35$1.45M88,606May 8, 2026May 8, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,404$72.57$174.5K166,202May 8, 2026May 8, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
33,513$73.72$2.47M132,689May 8, 2026May 8, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE
Chief Executive Officer
3,000——387,012Apr 16, 2026Apr 20, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
3,000$22.86$68.6K1,135,987Apr 16, 2026Apr 20, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
17,800$82.48$1.47M1,135,187Apr 8, 2026Apr 10, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,000$83.26$166.5K1,133,187Apr 8, 2026Apr 10, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
200$85.00$17.0K1,132,987Apr 8, 2026Apr 10, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,418$75.86$259.3K1,152,987Mar 11, 2026Mar 13, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,363$74.29$621.3K1,164,624Mar 11, 2026Mar 13, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,219$74.83$615.0K1,156,405Mar 11, 2026Mar 13, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
11,494$62.96$723.7K1,181,493Feb 11, 2026Feb 13, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
955$64.99$62.1K1,172,987Feb 11, 2026Feb 13, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,551$63.73$481.2K1,173,942Feb 11, 2026Feb 13, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASE
63,227——168,606Jan 21, 2026Jan 23, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
470$83.79$39.4K1,192,987Jan 14, 2026Jan 16, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,440$78.64$113.2K1,211,547Jan 14, 2026Jan 16, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,386$83.16$447.9K1,193,457Jan 14, 2026Jan 16, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,854$82.41$152.8K1,198,843Jan 14, 2026Jan 16, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,476$79.82$676.6K1,203,071Jan 14, 2026Jan 16, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,374$81.00$192.3K1,200,697Jan 14, 2026Jan 16, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
253,016——253,016Jan 2, 2026Jan 6, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
10,005$75.79$758.3K1,213,547Dec 10, 2025Dec 12, 2025 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
560$76.58$42.9K1,212,987Dec 10, 2025Dec 12, 2025 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
9,435$74.88$706.5K1,223,552Dec 10, 2025Dec 12, 2025 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
40,000$75.01$3.00M1,232,987Dec 4, 2025Dec 5, 2025 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,340$61.93$206.8K1,289,647Nov 13, 2025Nov 13, 2025 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
100$64.52$6.5K1,272,987Nov 13, 2025Nov 13, 2025 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,786$63.89$114.1K1,273,087Nov 13, 2025Nov 13, 2025 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
14,774$63.14$932.8K1,274,873Nov 13, 2025Nov 13, 2025 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——25,000May 29, 2025Jun 2, 2025 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,674$30.62$81.9K1,292,987Mar 5, 2025Mar 7, 2025 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,326$29.98$219.6K1,295,661Mar 5, 2025Mar 7, 2025 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
15,000$40.58$608.7K1,302,987Feb 5, 2025Feb 7, 2025 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
8,500$22.86$194.3K1,317,987Jan 31, 2025Jan 31, 2025 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE
Chief Executive Officer
8,500——390,012Jan 31, 2025Jan 31, 2025 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASE
105,379——105,379Jan 10, 2025Jan 14, 2025 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
12,132$48.72$591.1K1,312,355Jan 8, 2025Jan 10, 2025 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,868$49.38$141.6K1,309,487Jan 8, 2025Jan 10, 2025 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
357,036——357,036Dec 9, 2024Dec 11, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,672$47.19$78.9K1,324,487Dec 4, 2024Dec 6, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
13,328$46.50$619.8K1,326,159Dec 4, 2024Dec 6, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,000$59.94$59.9K1,339,487Nov 6, 2024Nov 8, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
14,000$59.17$828.4K1,340,487Nov 6, 2024Nov 8, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
9,712$56.74$551.1K1,354,487Oct 2, 2024Oct 4, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
30,288$56.07$1.70M1,364,199Oct 2, 2024Oct 4, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
14,359$48.23$692.5K1,394,487Sep 4, 2024Sep 6, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
25,641$47.28$1.21M1,408,846Sep 4, 2024Sep 6, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
100$42.17$4.2K1,434,487Aug 7, 2024Aug 9, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
32,233$40.40$1.30M1,442,254Aug 7, 2024Aug 9, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,667$41.52$318.3K1,434,587Aug 7, 2024Aug 9, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
15,000$37.26$558.9K1,474,487Jul 5, 2024Jul 5, 2024 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
11,323——11,323May 14, 2024May 16, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
398,512——398,512Dec 18, 2023Dec 20, 2023 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
3,137——3,137Dec 15, 2020Dec 17, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
2,199——2,199Dec 15, 2020Dec 17, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
4,456——4,456Dec 15, 2020Dec 17, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
Chief Business Officer
10,000$1.05$10.5K284,211Dec 1, 2020Dec 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
3,028$51.12$154.8K281,183Dec 1, 2020Dec 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
6,972$51.69$360.4K274,211Dec 1, 2020Dec 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
10,000——8,282Dec 1, 2020Dec 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
6,353$44.33$281.6K274,211Nov 16, 2020Nov 18, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
Chief Business Officer
10,000$1.05$10.5K277,751Nov 16, 2020Nov 18, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
12,813——179,375Nov 16, 2020Nov 18, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
10,000$45.00$450.0K267,751Nov 16, 2020Nov 18, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
10,000——18,282Nov 16, 2020Nov 18, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
Chief Business Officer
12,813——280,564Nov 16, 2020Nov 18, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
10,000——28,282Nov 2, 2020Nov 3, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
Chief Business Officer
10,000$1.05$10.5K277,751Nov 2, 2020Nov 3, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
500$38.92$19.5K267,751Nov 2, 2020Nov 3, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
9,500$38.33$364.1K268,251Nov 2, 2020Nov 3, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
6,745——38,282Oct 1, 2020Oct 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
1,019——0Oct 1, 2020Oct 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
5,505$39.28$216.2K267,751Oct 1, 2020Oct 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
4,495$38.29$172.1K273,256Oct 1, 2020Oct 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
Chief Business Officer
3,255$0.28$911271,006Oct 1, 2020Oct 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
2,236——0Oct 1, 2020Oct 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
Chief Business Officer
6,745$1.05$7.1K277,751Oct 1, 2020Oct 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
10,000$40.00$400.0K267,751Sep 18, 2020Sep 22, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
5,099——2,236Sep 18, 2020Sep 22, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
4,901——4,586Sep 18, 2020Sep 22, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
Chief Business Officer
5,099$0.28$1.4K277,751Sep 18, 2020Sep 22, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
Chief Business Officer
4,901$0.16$784272,652Sep 18, 2020Sep 22, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
10,000——9,487Sep 1, 2020Sep 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
5,022$27.89$140.1K272,729Sep 1, 2020Sep 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
4,978$29.58$147.3K267,751Sep 1, 2020Sep 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
Chief Business Officer
10,000$0.16$1.6K277,751Sep 1, 2020Sep 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
12,812——192,188Aug 16, 2020Aug 18, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
Chief Business Officer
12,812——273,211Aug 16, 2020Aug 18, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
5,460$28.53$155.8K267,751Aug 16, 2020Aug 18, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
1,103$28.11$31.0K260,293Aug 3, 2020Aug 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
10,000——19,487Aug 3, 2020Aug 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
8,897$27.28$242.7K261,396Aug 3, 2020Aug 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
Chief Business Officer
10,000$0.16$1.6K270,293Aug 3, 2020Aug 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
7,168$30.63$219.5K263,125Jul 1, 2020Jul 6, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
200$32.67$6.5K260,293Jul 1, 2020Jul 6, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
Chief Business Officer
10,000$0.16$1.6K270,293Jul 1, 2020Jul 6, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
10,000——29,487Jul 1, 2020Jul 6, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
2,632$31.77$83.6K260,493Jul 1, 2020Jul 6, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
506$30.00$15.2K260,393Jun 8, 2020Jun 10, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
100$30.05$3.0K260,293Jun 8, 2020Jun 10, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
784$30.04$23.5K261,399Jun 3, 2020Jun 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
2,085$29.26$61.0K262,183Jun 1, 2020Jun 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
500$29.79$14.9K261,683Jun 1, 2020Jun 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
Chief Business Officer
18,365$1.05$19.3K264,268May 26, 2020May 26, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Business Officer
18,365——0May 26, 2020May 26, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
7,335——7,335May 19, 2020May 21, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
19,271——19,271May 19, 2020May 21, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
18,365——18,365May 19, 2020May 21, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
39,487——39,487May 19, 2020May 21, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
205,000——205,000May 19, 2020May 21, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
13,932——13,932May 19, 2020May 21, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
1,019——1,019May 19, 2020May 21, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
3,351——3,351May 19, 2020May 21, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
7,778——7,778May 19, 2020May 21, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
83,541——245,903May 19, 2020May 21, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
45,027——45,027May 19, 2020May 21, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
1,460$30.47$44.5K162,362May 5, 2020May 5, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
1,320$30.01$39.6K163,822May 4, 2020May 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,285$29.19$66.7K165,442May 1, 2020May 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
300$29.87$9.0K165,142May 1, 2020May 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
1,100$27.56$30.3K167,727Apr 1, 2020Apr 3, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
44$25.40$1.1K170,268Apr 1, 2020Apr 3, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
1,441$26.51$38.2K168,827Apr 1, 2020Apr 3, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,575$32.20$82.9K171,712Mar 2, 2020Mar 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
1,400$32.89$46.0K170,312Mar 2, 2020Mar 4, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
3,975$34.90$138.7K174,287Feb 3, 2020Feb 5, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
332$32.28$10.7K178,288Jan 3, 2020Jan 6, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
26$33.00$858178,262Jan 3, 2020Jan 6, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
1,500$32.69$49.0K180,737Jan 2, 2020Jan 6, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,002$33.61$67.3K178,735Jan 2, 2020Jan 6, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
115$34.45$4.0K178,620Jan 2, 2020Jan 6, 2020 ↗View →
Other insiders · BBIO
Loading peer insiders…
About this filer
CIK 0001779990
ROLE
Chief Business Officer
PRIMARY
BBIO
COMPANIES
3
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001779990DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback